Acadian Asset Management’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$372K Buy
12,107
+7,757
+178% +$192K ﹤0.01% 1514
2026
Q1
$93K Buy
+4,350
New +$93.9K ﹤0.01% 1767
2025
Q4
– Sell
-32,358
Closed -$438K – 2094
2025
Q3
$438K Buy
+32,358
New +$336K ﹤0.01% 1255
2025
Q2
– Sell
-22,932
Closed -$180K – 1804
2025
Q1
$180K Sell
22,932
-7,871
-26% -$91.3K ﹤0.01% 1274
2024
Q4
$458K Buy
30,803
+29,507
+2,277% +$482K ﹤0.01% 1094
2024
Q3
$19K Buy
+1,296
New +$20.4K ﹤0.01% 1983
2023
Q2
– Sell
-1,444
Closed -$26K – 1878
2023
Q1
$26K Hold
1,444
– – ﹤0.01% 1623
2022
Q4
$29K Buy
+1,444
New +$39.7K ﹤0.01% 1660
2021
Q3
– Sell
-5,022
Closed -$137K – 1964
2021
Q2
$137K Sell
5,022
-3,576
-42% -$102K ﹤0.01% 1549
2021
Q1
$241K Buy
8,598
+5,938
+223% +$207K ﹤0.01% 1437
2020
Q4
$69K Buy
+2,660
New +$64.4K ﹤0.01% 1859
2020
Q3
– Sell
-954
Closed -$24K – 2321
2020
Q2
$24K Sell
954
-2,079
-69% -$56.1K ﹤0.01% 2102
2020
Q1
$42K Buy
+3,033
New +$37.7K ﹤0.01% 1539
2019
Q4
– Sell
-7,708
Closed -$70K – 2028
2019
Q3
$70K Buy
+7,708
New +$61.9K ﹤0.01% 1562

Other funds holding RCUS

Acadian Asset Management's RCUS Position: Q2 2026 in Review

Acadian Asset Management increased its Arcus Biosciences (RCUS) stake by 178% in Q2 2026, buying an estimated $192K and bringing the position to 12,107 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #1514.

Acadian Asset Management first reported a position in RCUS in Q3 2019 and has held it in 14 quarters since. The position peaked at $458K in Q4 2024. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Acadian Asset Management held 12,107 shares of Arcus Biosciences worth $372K as of Q2 2026.
  • Acadian Asset Management bought 7,757 Arcus Biosciences shares in Q2 2026, an estimated $192K.
  • Arcus Biosciences made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1514 holding.
  • Acadian Asset Management first reported a position in Arcus Biosciences in Q3 2019 and has held it in 14 quarters since.
  • Acadian Asset Management's Arcus Biosciences position peaked at $458K in Q4 2024.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.